Skip to main content

Table 1 Patient’s characteristic, overall and according to the treatment arms

From: Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer

Variable Overall No (%) Arm A FEC → TAXNo (%) Arm B TAX → FECNo (%)
Total 119 (100) 62 (52) 57 (48)
Age    
>50 67 (56) 22 (36) 30 (53)
≤50 52 (44) 40 (64) 27 (47)
Sex    
Female 119 (100) 62 (100) 57 (100)
Male 0 (0) 0 (0) 0 (0)
T stage    
T1 22 (18) 11 (18) 11 (19)
T2 78 (65) 41 (66) 37 (64)
T3 19 (17) 10 (16) 9 (17)
Nodal status    
Positive 96 (81) 51 (82) 45 (78)
Negative 23 (19) 11 (18) 12 (22)
Histological type    
IDC 108 (88.5) 57 (92) 51 (90)
ILD 11 (11.5) 5 (8) 6 (10)
Pathological grade    
1 or 2 46 (39) 22 (36) 24 (42)
3 73 (61) 40 (65) 33 (58)
Breast cancer subtype    
Luminal A 24 (20) 10 (16) 14 (24)
Luminal B 49 (41) 25 (40) 24 (42)
HER2 17 (14) 12 (19) 5 (9)
TN 29 (24) 15 (24) 14 (24)
Ki67 (N = 106)    
>20% 68 (64) 31 (57) 37 (71)
≤20% 38 (36) 23 (43) 15 (29)
Surgery    
Mastectomy 56 (47) 27 (44) 29 (51)
BCS 63 (53) 35 (56) 28 (49)
Response rates    
pCR 26 (22) 14 (23) 12 (21)
non pCR 93 (78) 48 (77) 45 (79)
  1. BCS, breast conserving surgery; FEC, fluorouracil, epirubicin, cyclophosphamide; TAX, docetaxel; TN, triple negative.